Virgin, S. Pathogenesis of viral infection. in Fields Virology, 5th edn, vol. 1 (eds. Knipe, D.M. & Howley, P.M. (Lippincott Williams & Wilkins, Philadelphia, 2007).
Cattaneo, R., Miest, T., Shashkova, E.V. & Barry, M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol.6, 529–540 (2008). CASPubMedPubMed Central Google Scholar
Dorer, D.E. & Nettelbeck, D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev.61, 554–571 (2009). CASPubMed Google Scholar
Naik, S. & Russell, S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin. Biol. Ther.9, 1163–1176 (2009). CASPubMed Google Scholar
Kelly, E.J. & Russell, S.J. MicroRNAs and the regulation of vector tropism. Mol. Ther.17, 409–416 (2009). CASPubMed Google Scholar
Kelly, E. & Russell, S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther.15, 651–659 (2007). CASPubMed Google Scholar
Southam, C.M. Present status of oncolytic virus studies. Trans. N.Y. Acad. Sci.22, 657–673 (1960). CASPubMed Google Scholar
Asada, T. Treatment of human cancer with mumps virus. Cancer34, 1907–1928 (1974). CASPubMed Google Scholar
Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. & Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science252, 854–856 (1991). CASPubMed Google Scholar
Au, G.G., Lindberg, A.M., Barry, R.D. & Shafren, D.R. Oncolysis of vascular malignant human melanoma tumors by coxsackievirus A21. Int. J. Oncol.26, 1471–1476 (2005). CASPubMed Google Scholar
Rudin, C.M. et al. Phase I clinical study of Seneca Valley virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin. Cancer Res.17, 888–895 (2011). CASPubMedPubMed Central Google Scholar
Tai, C.K. & Kasahara, N. Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci.13, 3083–3095 (2008). CASPubMed Google Scholar
Liu, T.C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol.4, 101–117 (2007). CASPubMed Google Scholar
Schoofs, G. et al. A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology28, 81–89 (1998). CASPubMedPubMed Central Google Scholar
Knop, D.R. & Harrell, H. Bioreactor production of recombinant herpes simplex virus vectors. Biotechnol. Prog.23, 715–721 (2007). CASPubMed Google Scholar
Lewis, J.A., Brown, E.L. & Duncan, P.A. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. Biol. (Basel)123, 165–176, discussion 183–197 (2006). CAS Google Scholar
Russell, S.J. Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol.5, 437–443 (1994). CASPubMed Google Scholar
Senzer, N.N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol.27, 5763–5771 (2009). CASPubMed Google Scholar
Park, B.H. et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol.9, 533–542 (2008). CASPubMed Google Scholar
Eager, R.M. & Nemunaitis, J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther.18, 305–317 (2011). CASPubMed Google Scholar
Mastrangelo, M.J. et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther.6, 409–422 (1999). CASPubMed Google Scholar
Harrington, K.J. et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res.16, 4005–4015 (2010). CASPubMed Google Scholar
Harrington, K.J., Vile, R.G., Melcher, A., Chester, J. & Pandha, H.S. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev.21, 91–98 (2010). CASPubMedPubMed Central Google Scholar
Heo, J. et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther.19, 1170–1179 (2011). CASPubMedPubMed Central Google Scholar
Peng, K.W., Facteau, S., Wegman, T., O'Kane, D. & Russell, S.J. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med.8, 527–531 (2002). CASPubMed Google Scholar
Kelly, E.J., Hadac, E.M., Greiner, S. & Russell, S.J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med.14, 1278–1283 (2008). CASPubMed Google Scholar
Naik, S. et al. Curative one-shot systemic virotherapy in murine myeloma. Leukemia published online, 10.1038/leu.2012.70 (19 March 2012).
Breitbach, C.J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature477, 99–102 (2011). CASPubMed Google Scholar
Serganova, I., Ponomarev, V. & Blasberg, R. Human reporter genes: potential use in clinical studies. Nucl. Med. Biol.34, 791–807 (2007). CASPubMed Google Scholar
Galanis, E. et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res.70, 875–882 (2010). CASPubMedPubMed Central Google Scholar
Jacobs, A. et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet358, 727–729 (2001). CASPubMed Google Scholar
Dingli, D., Russell, S.J. & Morris, J.C. III. In vivo imaging and tumor therapy with the sodium iodide symporter. J. Cell. Biochem.90, 1079–1086 (2003). CASPubMed Google Scholar
Barton, K.N. et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther.16, 1761–1769 (2008). CASPubMed Google Scholar
Dingli, D. et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood103, 1641–1646 (2004). CASPubMed Google Scholar
Underhill, D.M. & Ozinsky, A. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol.20, 825–852 (2002). CASPubMed Google Scholar
Haisma, H.J. et al. Scavenger receptor A: a new route for adenovirus 5. Mol. Pharm.6, 366–374 (2009). CASPubMed Google Scholar
Bessis, N., GarciaCozar, F.J. & Boissier, M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther.11 (suppl. 1), S10–S17 (2004). CASPubMed Google Scholar
Fisher, K.D. & Seymour, L.W. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev.62, 240–245 (2010). CASPubMed Google Scholar
Eto, Y., Yoshioka, Y., Mukai, Y., Okada, N. & Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm.354, 3–8 (2008). CASPubMed Google Scholar
Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6, 688–701 (2006). CASPubMed Google Scholar
Morrison, J. et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther.16, 244–251 (2008). CASPubMed Google Scholar
Croyle, M.A. et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol.78, 912–921 (2004). CASPubMedPubMed Central Google Scholar
Alemany, R., Suzuki, K. & Curiel, D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol.81, 2605–2609 (2000). CASPubMed Google Scholar
Doronin, K., Shashkova, E.V., May, S.M., Hofherr, S.E. & Barry, M.A. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther.20, 975–988 (2009). CASPubMedPubMed Central Google Scholar
Green, N.K. et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther.11, 1256–1263 (2004). CASPubMed Google Scholar
Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med.5, 881–887 (1999). CASPubMed Google Scholar
Ikeda, K. et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol.74, 4765–4775 (2000). CASPubMedPubMed Central Google Scholar
Wakimoto, H. et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther.5, 275–282 (2002). CASPubMed Google Scholar
Haisma, H.J. & Bellu, A.R. Pharmacological interventions for improving adenovirus usage in gene therapy. Mol. Pharm.8, 50–55 (2011). CASPubMed Google Scholar
Shashkova, E.V., Doronin, K., Senac, J.S. & Barry, M.A. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res.68, 5896–5904 (2008). CASPubMed Google Scholar
Koski, A. et al. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J. Gene Med.11, 966–977 (2009). CASPubMed Google Scholar
Ziegler, R.J. et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum. Gene Ther.13, 935–945 (2002). CASPubMed Google Scholar
Manickan, E. et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol. Ther.13, 108–117 (2006). CASPubMed Google Scholar
Tao, N. et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther.3, 28–35 (2001). CASPubMed Google Scholar
Power, A.T. & Bell, J.C. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther.15, 772–779 (2008). CASPubMed Google Scholar
Ilett, E.J. et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther.16, 689–699 (2009). CASPubMedPubMed Central Google Scholar
Liu, C., Russell, S.J. & Peng, K.W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther.18, 1155–1164 (2010). CASPubMedPubMed Central Google Scholar
Dwyer, R.M., Khan, S., Barry, F.P., O'Brien, T. & Kerin, M.J. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res. Ther.1, 25 (2010). PubMedPubMed Central Google Scholar
García-Castro, J. et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther.17, 476–483 (2010). PubMed Google Scholar
Ling, X. et al. Mesenchymal stem cells overexpressing IFN-β inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron.3, 83–95 (2010). CASPubMedPubMed Central Google Scholar
Mader, E.K. et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res.15, 7246–7255 (2009). CASPubMedPubMed Central Google Scholar
Ilett, E.J. et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin. Cancer Res.17, 2767–2776 (2011). CASPubMedPubMed Central Google Scholar
Qiao, J. et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther.15, 604–616 (2008). CASPubMedPubMed Central Google Scholar
Ong, H.T., Hasegawa, K., Dietz, A.B., Russell, S.J. & Peng, K.W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther.14, 324–333 (2007). CASPubMed Google Scholar
Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46, 6387–6392 (1986). CASPubMed Google Scholar
Fang, J., Nakamura, H. & Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63, 136–151 (2011). CASPubMed Google Scholar
Hobbs, S.K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA95, 4607–4612 (1998). CASPubMedPubMed Central Google Scholar
Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol.156, 1363–1380 (2000). CASPubMedPubMed Central Google Scholar
Jain, R.K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol.7, 653–664 (2010). CASPubMedPubMed Central Google Scholar
Fox, M.E., Szoka, F.C. & Frechet, J.M. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc. Chem. Res.42, 1141–1151 (2009). CASPubMedPubMed Central Google Scholar
Barnett, F.H. et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther.6, 14–20 (1999). CASPubMed Google Scholar
Tseng, J.C., Granot, T., DiGiacomo, V., Levin, B. & Meruelo, D. Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther.17, 244–255 (2010). CASPubMed Google Scholar
Kottke, T. et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J. Clin. Invest.120, 1551–1560 (2010). CASPubMedPubMed Central Google Scholar
Kottke, T. et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther.16, 1217–1226 (2008). CASPubMed Google Scholar
Driessen, W.H., Ozawa, M.G., Arap, W. & Pasqualini, R. Ligand-directed cancer gene therapy to angiogenic vasculature. Adv. Genet.67, 103–121 (2009). CASPubMedPubMed Central Google Scholar
Thorne, S.H. et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest.117, 3350–3358 (2007). CASPubMedPubMed Central Google Scholar
Neri, D. & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer5, 436–446 (2005). CASPubMed Google Scholar
Sanz, L. et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther.9, 1049–1053 (2002). CASPubMed Google Scholar
Palumbo, A. et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer104, 1106–1115 (2011). CASPubMedPubMed Central Google Scholar
Nakamura, T. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol.23, 209–214 (2005). CASPubMed Google Scholar
Morrison, J. et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum. Gene Ther.20, 239–251 (2009). CASPubMed Google Scholar
Bachtarzi, H. et al. Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. J. Control. Release150, 196–203 (2011). CASPubMedPubMed Central Google Scholar
Ong, H.T. et al. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther.17, 1012–1021 (2009). CASPubMedPubMed Central Google Scholar
Jing, Y. et al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res.69, 1459–1468 (2009). CASPubMedPubMed Central Google Scholar
Kumar, C.C. et al. Biochemical characterization of the binding of echistatin to integrin αvβ3 receptor. J. Pharmacol. Exp. Ther.283, 843–853 (1997). CASPubMed Google Scholar
Chen, H.H. et al. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol. Ther.19, 67–75 (2011). CASPubMed Google Scholar
Stojdl, D.F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell4, 263–275 (2003). CASPubMed Google Scholar
Schoggins, J.W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature472, 481–485 (2011). CASPubMedPubMed Central Google Scholar
Haller, O., Kochs, G. & Weber, F. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev.18, 425–433 (2007). CASPubMedPubMed Central Google Scholar
Vandevenne, P., Sadzot-Delvaux, C. & Piette, J. Innate immune response and viral interference strategies developed by human herpesviruses. Biochem. Pharmacol.80, 1955–1972 (2010). CASPubMed Google Scholar
Lu, M.Y. & Liao, F. Interferon-stimulated gene ISG12b2 is localized to the inner mitochondrial membrane and mediates virus-induced cell death. Cell Death Differ.18, 925–936 (2011). CASPubMed Google Scholar
Stojdl, D.F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med.6, 821–825 (2000). CASPubMed Google Scholar
Haralambieva, I. et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther.15, 588–597 (2007). CASPubMed Google Scholar
Altomonte, J. et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol. Ther.16, 146–153 (2008). CASPubMed Google Scholar
Le Boeuf, F. et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther.18, 888–895 (2010). CASPubMedPubMed Central Google Scholar
Kirn, D.H. & Thorne, S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer9, 64–71 (2009). CASPubMed Google Scholar
Chang, H.M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. USA101, 9578–9583 (2004). CASPubMedPubMed Central Google Scholar
Nguyên, T.L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. USA105, 14981–14986 (2008). PubMedPubMed Central Google Scholar
Otsuki, A. et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther.16, 1546–1555 (2008). CASPubMed Google Scholar
MacTavish, H. et al. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE5, e14462 (2010). CASPubMedPubMed Central Google Scholar
Diallo, J.S. et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther.18, 1123–1129 (2010). CASPubMedPubMed Central Google Scholar
Passer, B.J. et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res.70, 3890–3895 (2010). CASPubMedPubMed Central Google Scholar
Alain, T. et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl. Acad. Sci. USA107, 1576–1581 (2010). CASPubMedPubMed Central Google Scholar
Lun, X. et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res.70, 598–608 (2010). CASPubMed Google Scholar
Lun, X.Q. et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res.67, 8818–8827 (2007). CASPubMedPubMed Central Google Scholar
Qiao, J. et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res.14, 259–269 (2008). CASPubMedPubMed Central Google Scholar
Kottke, T. et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin. Cancer Res.15, 561–569 (2009). CASPubMedPubMed Central Google Scholar
Kurozumi, K. et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst.99, 1768–1781 (2007). CASPubMed Google Scholar
Kirn, D.H., Wang, Y., Liang, W., Contag, C.H. & Thorne, S.H. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res.68, 2071–2075 (2008). CASPubMed Google Scholar
Reeves, P.M. et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J. Virol.85, 21–31 (2011). CASPubMed Google Scholar
Hoffmann, D. & Wildner, O. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol. Cancer Ther.5, 2013–2022 (2006). CASPubMed Google Scholar
Patel, B. et al. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol. Ther.19, 1034–1040 (2011). CASPubMedPubMed Central Google Scholar
Israyelyan, A. et al. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol. J.5, 68 (2008). PubMedPubMed Central Google Scholar
Brown, C.W. et al. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J. Virol.83, 552–561 (2009). CASPubMed Google Scholar
Sauthoff, H. et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther.14, 425–433 (2003). CASPubMed Google Scholar
Yun, C.O. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther.10, 356–361 (2008). PubMed Google Scholar
Diop-Frimpong, B., Chauhan, V.P., Krane, S., Boucher, Y. & Jain, R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA108, 2909–2914 (2011). CASPubMedPubMed Central Google Scholar
Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Van Roey, M. & Jooss, K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res.14, 3933–3941 (2008). CASPubMed Google Scholar
Guedan, S. et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther.18, 1275–1283 (2010). CASPubMedPubMed Central Google Scholar
Toth, K., Dhar, D. & Wold, W.S. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin. Biol. Ther.10, 353–368 (2010). CASPubMed Google Scholar
Muthana, M. et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res.71, 1805–1815 (2011). CASPubMed Google Scholar
Lee, C.Y.F. et al. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol. Ther.18, 929–935 (2010). CASPubMedPubMed Central Google Scholar
Foka, P. et al. Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J. Gene Med.12, 956–967 (2010). CASPubMed Google Scholar
Muik, A. et al. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J. Virol.85, 5679–5684 (2011). CASPubMedPubMed Central Google Scholar
Ayala Breton, C., Barber, G.N., Russell, S. & Peng, K.W. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum. Gene Ther.23, 484–491 (2012). CASPubMed Google Scholar
Shashkova, E.V., May, S.M., Doronin, K. & Barry, M.A. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol. Ther.17, 2121–2130 (2009). CASPubMedPubMed Central Google Scholar
Leber, M.F. et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol. Ther.19, 1097–1106 (2011). CASPubMedPubMed Central Google Scholar
Cawood, R., Wong, S.L., Di, Y., Baban, D.F. & Seymour, L.W. MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity. PLoS ONE6, e16152 (2011). CASPubMedPubMed Central Google Scholar
Cawood, R. et al. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog.5, e1000440 (2009). PubMedPubMed Central Google Scholar
Kelly, E.J., Nace, R., Barber, G.N. & Russell, S.J. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J. Virol.84, 1550–1562 (2010). CASPubMed Google Scholar
Edge, R.E. et al. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther.16, 1437–1443 (2008). CASPubMed Google Scholar
Sugio, K. et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin. Cancer Res.17, 2807–2818 (2011). CASPubMed Google Scholar
Yang, X. et al. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J. Virol. Methods155, 44–54 (2009). CASPubMed Google Scholar
Roos, F.C. et al. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol. Med.2, 275–288 (2010). CASPubMedPubMed Central Google Scholar
Oliere, S. et al. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J. Virol.82, 5735–5749 (2008). CASPubMedPubMed Central Google Scholar
Stoff-Khalili, M.A. et al. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res. Treat.108, 43–55 (2008). CASPubMed Google Scholar
Banaszynski, L.A., Sellmyer, M.A., Contag, C.H., Wandless, T.J. & Thorne, S.H. Chemical control of protein stability and function in living mice. Nat. Med.14, 1123–1127 (2008). CASPubMedPubMed Central Google Scholar
Glass, M., Busche, A., Wagner, K., Messerle, M. & Borst, E.M. Conditional and reversible disruption of essential herpesvirus proteins. Nat. Methods6, 577–579 (2009). CASPubMed Google Scholar
Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G. & Wandless, T.J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell126, 995–1004 (2006). CASPubMedPubMed Central Google Scholar
Stepkowski, S.M. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med.2, 1–23 (2000). CASPubMed Google Scholar
Chiocca, E.A. The host response to cancer virotherapy. Curr. Opin. Mol. Ther.10, 38–45 (2008). PubMed Google Scholar
Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell144, 646–674 (2011). CASPubMed Google Scholar
Yang, L., Pang, Y. & Moses, H.L. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol.31, 220–227 (2010). CASPubMedPubMed Central Google Scholar
Melcher, A., Parato, K., Rooney, C.M. & Bell, J.C. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther.6, 1008–1016 (2011). Google Scholar
Mastrangelo, M.J., Maguire, H.C. & Lattime, E.C. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol.465, 391–400 (2000). CASPubMed Google Scholar
Diaz, R.M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res.67, 2840–2848 (2007). CASPubMed Google Scholar
Bridle, B.W., Hanson, S. & Lichty, B.D. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev.21, 143–148 (2010). CASPubMed Google Scholar
Kottke, T. et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat. Med.17, 854–859 (2011). CASPubMedPubMed Central Google Scholar
Pulido, J. et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat. Biotechnol.30, 337–343 (2012). CASPubMedPubMed Central Google Scholar
Kottke, T. et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther.16, 1910–1918 (2008). CASPubMed Google Scholar
Senac, J.S. et al. Infection and killing of multiple myeloma by adenoviruses. Hum. Gene Ther.21, 179–190 (2010). CASPubMed Google Scholar
Zhang, X., Zhao, L., Hang, Z., Guo, H. & Zhang, M. Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol. Rep.26, 637–644 (2011). CASPubMed Google Scholar
Kanai, R., Wakimoto, H., Cheema, T. & Rabkin, S.D. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol.6, 619–634 (2010). PubMed Google Scholar
Byrnes, A.P. & Griffin, D.E. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J. Virol.74, 644–651 (2000). CASPubMedPubMed Central Google Scholar
Lee, P., Knight, R., Smit, J.M., Wilschut, J. & Griffin, D.E. A single mutation in the E2 glycoprotein important for neurovirulence influences binding of sindbis virus to neuroblastoma cells. J. Virol.76, 6302–6310 (2002). CASPubMedPubMed Central Google Scholar
Chen, N. et al. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy. Virology409, 328–337 (2011). CASPubMed Google Scholar
Peng, K.W. et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther. published, online doi:10.1038/gt.2012.31 (5 April 2012). CASPubMed Google Scholar
Miyatake, S., Iyer, A., Martuza, R.L. & Rabkin, S.D. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol.71, 5124–5132 (1997). CASPubMedPubMed Central Google Scholar
Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res.57, 2559–2563 (1997). CASPubMed Google Scholar
Kuhn, I. et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE3, e2409 (2008). PubMedPubMed Central Google Scholar
Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol.74, 6147–6155 (2000). CASPubMedPubMed Central Google Scholar
Wong, R.J. et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther.12, 253–265 (2001). CASPubMed Google Scholar
Kim, J.H. et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst.98, 1482–1493 (2006). CASPubMed Google Scholar
Thorne, S.H., Negrin, R.S. & Contag, C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science311, 1780–1784 (2006). CASPubMed Google Scholar